AU3959193A - Heterocyclic compounds and their use in the treatment of type II-diabetes - Google Patents
Heterocyclic compounds and their use in the treatment of type II-diabetesInfo
- Publication number
- AU3959193A AU3959193A AU39591/93A AU3959193A AU3959193A AU 3959193 A AU3959193 A AU 3959193A AU 39591/93 A AU39591/93 A AU 39591/93A AU 3959193 A AU3959193 A AU 3959193A AU 3959193 A AU3959193 A AU 3959193A
- Authority
- AU
- Australia
- Prior art keywords
- diabetes
- treatment
- type
- heterocyclic compounds
- heterocyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929208016A GB9208016D0 (en) | 1992-04-10 | 1992-04-10 | Novel compounds |
| GB9208016 | 1992-04-10 | ||
| GB929208451A GB9208451D0 (en) | 1992-04-16 | 1992-04-16 | Novel compounds |
| GB9208451 | 1992-04-16 | ||
| GB929227047A GB9227047D0 (en) | 1992-12-29 | 1992-12-29 | Novel compounds |
| GB9227047 | 1992-12-29 | ||
| GB9227046 | 1992-12-29 | ||
| GB929227046A GB9227046D0 (en) | 1992-12-29 | 1992-12-29 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU3959193A true AU3959193A (en) | 1993-11-18 |
Family
ID=27450858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU39591/93A Abandoned AU3959193A (en) | 1992-04-10 | 1993-04-07 | Heterocyclic compounds and their use in the treatment of type II-diabetes |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0635007A1 (en) |
| JP (1) | JPH07505647A (en) |
| AU (1) | AU3959193A (en) |
| MX (1) | MX9302088A (en) |
| WO (1) | WO1993021166A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090836A (en) * | 1996-02-02 | 2000-07-18 | Merck & Co., Inc. | Benzisoxazole-derived antidiabetic compounds |
| US5847008A (en) * | 1996-02-02 | 1998-12-08 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
| US6020382A (en) * | 1996-02-02 | 2000-02-01 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
| US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
| GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| AU719663B2 (en) * | 1996-12-23 | 2000-05-11 | Merck & Co., Inc. | Antidiabetic agents |
| US6090839A (en) * | 1996-12-23 | 2000-07-18 | Merck & Co., Inc. | Antidiabetic agents |
| US6160000A (en) * | 1996-12-23 | 2000-12-12 | Merck & Co., Inc. | Antidiabetic agents based on aryl and heteroarylacetic acids |
| NZ501163A (en) | 1997-06-18 | 2002-02-01 | Smithkline Beecham P | Treatment of diabetes with thiazolidinedione and sulphonylurea (glibenclamide, glipizide, gliclazide, glimepiride, tolazamide and tolbutamide |
| EA007610B1 (en) | 1998-11-12 | 2006-12-29 | Смитклайн Бичам Плс | Enteric coated tablet providing sustained release |
| AR023699A1 (en) | 1998-11-12 | 2002-09-04 | Smithkline Beecham Corp | A PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INSULIN STABILIZER AND A PROCEDURE TO PREPARE A PHARMACEUTICAL COMPOSITION |
| DK1206457T3 (en) | 1999-08-27 | 2004-02-16 | Lilly Co Eli | Biaryl-oxa (thia) zole derivatives and their use as modulators PPAPs |
| US6768008B2 (en) * | 2000-04-24 | 2004-07-27 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
| US6784199B2 (en) | 2000-09-21 | 2004-08-31 | Aryx Therapeutics | Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals |
| US6680387B2 (en) | 2000-04-24 | 2004-01-20 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
| US6958355B2 (en) | 2000-04-24 | 2005-10-25 | Aryx Therapeutics, Inc. | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
| AU2001269821A1 (en) | 2000-06-15 | 2001-12-24 | Barbara Chen | Cycloalkyl alkanoic acids as integrin receptor antagonists |
| GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
| US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| JP4855777B2 (en) * | 2003-12-26 | 2012-01-18 | 武田薬品工業株式会社 | Phenylpropanoic acid derivatives |
| PL372332A1 (en) | 2005-01-19 | 2006-07-24 | ADAMED Sp.z o.o. | New compounds, derivatives of 3-phenylpropionic acid |
| WO2008139879A1 (en) * | 2007-04-26 | 2008-11-20 | Pharmafrontier, Co., Ltd. | G protein-coupled receptor inhibitor and pharmaceutical product |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0842925A1 (en) * | 1987-09-04 | 1998-05-20 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
| GB9017218D0 (en) * | 1990-08-06 | 1990-09-19 | Beecham Group Plc | Novel compounds |
-
1993
- 1993-04-07 EP EP93909044A patent/EP0635007A1/en not_active Withdrawn
- 1993-04-07 AU AU39591/93A patent/AU3959193A/en not_active Abandoned
- 1993-04-07 JP JP5518096A patent/JPH07505647A/en active Pending
- 1993-04-07 WO PCT/GB1993/000735 patent/WO1993021166A1/en not_active Application Discontinuation
- 1993-04-12 MX MX9302088A patent/MX9302088A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0635007A1 (en) | 1995-01-25 |
| WO1993021166A1 (en) | 1993-10-28 |
| MX9302088A (en) | 1994-07-29 |
| JPH07505647A (en) | 1995-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU3959193A (en) | Heterocyclic compounds and their use in the treatment of type II-diabetes | |
| AU673703B2 (en) | Injector and use of the same | |
| AU3482495A (en) | Substituted heteroaromatic compounds and their use in medicine | |
| AU6566094A (en) | Heterocyclic derivatives in the treatment of ischaemia and related diseases | |
| AU4673393A (en) | Use of 3-phenoxypyridine in the treatment of psychomotor stimulant addiction | |
| AU4009795A (en) | Heterocyclic compounds and their use | |
| KR100321237B1 (en) | Laminate and use of the same | |
| ZA941993B (en) | Amidine derivatives containing heterocyclic groups the preparation and use thereof | |
| AU2466695A (en) | The use of famotidine and related compounds in the treatment of movement disorders | |
| AU3551993A (en) | Tetraazacyclododecane derivative and its use | |
| ZA941926B (en) | Heterocyclic compounds their preparation and use | |
| AU9052991A (en) | Use of angiotensin ii antagonist in the treatment of infarction | |
| AU4100593A (en) | Iminoalcohol-oxazolidine mixtures and their use | |
| AU8427091A (en) | Gamma-carboxylase and methods of use | |
| AU4787593A (en) | Heterocyclic derivatives useful in the treatment of cardiovascular diseases | |
| AU4812393A (en) | Use of rapamycin in the treatment of aids | |
| AU4319393A (en) | Use of indolocarbazols in aids treatment | |
| AU2705495A (en) | Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory | |
| AU1292995A (en) | Bis-oxazolidine compounds and their use | |
| AU671860B2 (en) | Use of furancarboxamides in the protection of materials | |
| AU1485197A (en) | Diamines in the treatment of arrhythmia | |
| AU5656994A (en) | Chiral arylpropionates and their use | |
| AU4704393A (en) | Heterocyclic compounds and their use as herbicides | |
| NO942686D0 (en) | Use of 3-arylindole and 3-arylindazole derivatives in the treatment of psychoses | |
| AU1745092A (en) | Thiazolidine derivatives and their use in therapy |